New hope for aggressive leukemia? drug combo targets tough genetic mutation
NCT ID NCT07511062
First seen Apr 07, 2026 · Last updated May 14, 2026 · Updated 5 times
Summary
This early-stage study tests a new drug called axatilimab added to standard chemotherapy for people with a specific, high-risk form of acute myeloid leukemia (AML) that has a TP53 mutation or deletion. The goal is to find the safest dose of axatilimab and see how well the combination works at clearing leukemia from the bone marrow. About 32 adults who have not been treated before or whose cancer has returned will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northside Hospital, Inc.
Atlanta, Georgia, 30342, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.